Table 1 Fifty percent inhibitory concentration (IC50) and combination index (CI) of Clarithromycin, Irinotecan, 5-Fluorouracil, Cisplatin, and Oxaliplatin for the reported cancer cell lines.
(a) IC50 values of Clarithromycin for different cell lines | ||||
---|---|---|---|---|
Drug | Cell line | IC50 (μM) | ||
Clarithromycin | ||||
HCT116 | 80.0 ± 2.0 | |||
HT29 | 125.3 ± 16.8 | |||
LS174T | 154.4 ± 9.1 | |||
HCT116 p53−/− | 150.0 ± 8.6 | |||
HEK293 | >200 | |||
HEK293-MOCK | >200 | |||
HEK293-hERG1 | 92.4 ± 4.9 | |||
(b) IC50 and IC25 values of Irinotecan (CPT11), 5-Fluorouracil (5-FU), Cisplatin (Cis), and Oxaliplatin (Oxa), and their combination index (CI) with Clarithromycin for HCT116 cells | ||||
Drug | IC50 (μM) | IC25 (μM) | CI at IC50 (effect) | CI at IC25 (effect) |
CPT-11 | 10.1 ± 2.1 | 2.1 ± 0.1 | 0.63 ± 0.09 (S) | 0.41 ± 0.02 (S) |
5-FU | 13.7 ± 2.4 | 2.21 ± 0.1 | 0.57 ± 0.07 (S) | 0.38 ± 0.03 (S) |
Cis | 25.2 ± 2.1 (Ref. 50) | 9.04 ± 0.7 | 1.38 ± 0.06 (A) | 0.87 ± 0.15 (S) |
Oxa | 57.4 ± 9.4 (Ref. 50) | 12.2 ± 3.0 | 1.10 ± 0.11 (A) | 0.78 ± 0.10 (S) |
(c) IC50 and IC25 values of Clarithromycin and 5-Fluorouracil for HCT116 cells cultured as spheroids | ||||
Drug | IC50 (μM) | IC25 (μM) | ||
Clarithromycin | >300 | 191.8 ± 21.3 | ||
5-FU | 260.8 ± 4.6 | 41.7 ± 8.9 |